18-12-2023 | Metastasis | ASO Research Letter
Intra-Patient Heterogeneity in Micro-satellite-stable Colorectal Metastases: Does Immunotherapy Have a Role in Colorectal Peritoneal Metastases?
Authors:
M. B. Mirza, MD, P. Marincola Smith, MD, PhD, Y. Wang, PhD, A. Naveed, MD, M. K. Washington, MD, PhD, Y. Xu, PhD, K. Idrees, MD, MSCI, MMHC, FACS
Published in:
Annals of Surgical Oncology
|
Issue 3/2024
Login to get access
Excerpt
Metastatic disease is the leading cause of death for patients with colorectal cancer (CRC). More than 95 % of metastatic CRSs (mCRCs) are micro-satellite stable (MSS), and immunotherapy remains unapproved for this subgroup.
1 Colorectal peritoneal metastasis (CPM), which affects up to one fourth of patients with CRC, is associated with worse survival outcomes than liver and lung metastasis,
1 largely due to its aggressive biology and poor response to conventional chemotherapy.
2 These facts highlight the dire need for a deeper understanding of CPM disease biology and exploration of alternative therapies for patients with CPM.
3 In this study, a comprehensive genetic and immunophenotypic analysis of CPM was performed for two treatment-naïve patients with MSS-CRC. …
